The authors found that downregulation of TMEM106B in Hela cells (but not in primary neurons) causes a clustering of LAMP2-positive organelles in the perinuclear region, suggesting a role for TMEM106B in lysosomal trafficking and/or positioning. In hippocampal neurons, downregulation of TMEM106B alters dendritic and axonal morphology in apparent opposite ways, causing an increase in axonal length (which was not explored further) and a loss of dendrite complexity. Furthermore, knockdown of TMEM106B induces a loss of synaptic proteins and alterations in spine morphology. Interestingly, the dendritic phenotype is phenocopied by overexpression of MAP6, a novel binding partner of TMEM106B. The authors ascribed these effects on dendritic arborisation to changes in late endosome and lysosome mobility, which is increased by downregulation of TMEM106B or overexpression of MAP6.
Based on the impact of TMEM106B in neurodegeneration, these results are potentially interesting and overall, of high quality. However, this work falls short in convincingly demonstrating that TMEM106B regulates dendritic morphogenesis via an alteration of lysosomal trafficking. Furthermore, it is unclear how this in vitro function relates to the role of TMEM106B in vivo and/or in FTLD.
Specific comments: 1. The phenotype found by knockdown of TMEM106B in Hela cells is interesting but is not found in primary neurons. Given that the functional analysis of TMEM106B in neurons is the main focus of this study, Figures 1 and S1 are therefore redundant.
2. The distribution of TMEM106B in neurons and its colocalisation with LAMP1 have already been reported (J Neurosci. 2012 32(33) : 11213-11227), making panel 2A redundant as presently shown. However, it may be useful if completed with a quantitative analysis of the relative distribution of TMEM106B in axons and dendrites and its colocalisation with LAMP1. Furthermore, the distributions of LAMP1 in Figure 2 and S2 are very different, raising concerns on the heterogeneity of cells and possibly phenotype.
3. A phenotype generated by TMEM106B knockdown is the increase in primary dendrite length (more visible with shRNA 1; Figure 3B ) at DIV7+5. This effect mimics the increase in axonal length, which was pinpointed by the authors but not further investigated. How is this effect fitting with the model shown in Figure 8 ? Is a defect in lysosomal dynamics found in axons and dendrites at this stage of development? If present, do lysosomes move faster or slower (see Figure 6 )? 4. Why overexpression of T106B does not cause an increase in distal branching as MAP6 downregulation? This phenotype is also not triggered by nocodazole treatment, demonstrating that these treatments do not completely phenocopy each other.
5. The speed and the frequency of lysosomal movement in the experimental conditions of Figure 6 and S5 are rather low for a cytoplasmic dynein based process -only one lysosome seems moving in the kymograph in Figure 5A . The effect of TMEM106B knockdown is noticeable but rather limited. Is this the case in axons as well? Are the effects of TMEM106B knockdown on the dynamics of lysotracker-positive organelles similar?
6. The percentage of moving lysosomes in shMAP6 double knockdown samples seems much higher than shCtrl ( Figure 7A, B ), yet the relative vesicle number of moving organelles is very similar in the quantification in panel 7C. Are these kymographs representative? The results shown in this figure do not support the link between the altered dendritic transport of lysosomes and dendritic branching and the phenotypes shown in Figures 5 and 6 . 7. One of the predictions of the model shown in Figure 8 is that the modulation of lysosome transport by TMEM106B and MAP6 should be different in proximal and distal dendrites. Is this the case? 8. Page 3-4. The relationship of the different TMEM106B variants with human neurodegeneration is not very clearly explained. The wording should be simplified and made more precise in places (e.g. transmembrane domain in type 2 orientation).
Referee #2: In this paper the authors have investigated the relevance of TMEM106B and MAP6 proteins in dendritic arborization through lysosomal trafficking. The authors have shown good evidence that the functional relationship between these protein expression and the phenotypes due to overexpression and knockdown experiments, which is interesting and perhaps merits for the elucidation of the pathogenesis of FTLD neurogenerative disease. Furthermore, they have biochemically shown the association between these proteins and their cofractionation to the lysosomes. Conceptually, the weak point of this study would be that it is not clear why lysosomal trafficking affects dendritic arborization. Accordingly, this reviewer requests the following additional experiments before recommending its publication.
Specific points 1. The RNAi studies missed its controls for a nonspecific downregulation. Plasmid rescue study using RNAi-immune cDNA expression vectors should be added.
2. Fig 2a. The significance and specificity of the TMEM106B/Lamp1 colocalization should be statistically tested using an appropriate negative control. Does MAP6 also colocalize to lysosomes? 3. Figure 3 . Long-term dual-color time lapse study of dendritic arborization and lysosomal trafficking should better explain the functional relationship between these two phenotypes.
4. Figure 4 . Please also show the colocalization of MAP6 and TMEM106B to the lysosomes by fluorescently-tagged construct transfection. Y2H results should be precisely included to show what domains of these molecules are responsible for the interaction. The present study examined the role of TMEM106B, a transmembrane protein that is a risk factor for frontotemporal lobar degeneration with TDP-43 pathology. The authors found that TMEM106B mRNA knockdown in primary neurons affects lysosomal trafficking and blunts dendritic arborization. As a novel interacting protein, they identified MAP6, overexpression of which inhibits dendritic branching similar to TMEM106B knockdown. Moreover, they showed that retrograde transport of lysosomes in dendrites is increased by TMEM106B knockdown or MAP6 overexpression. Loss of dendritic branching caused by TMEM106B knockdown is rescued by MAP6 knockdown that inhibits increased retrograde transport of lysosomes and loss of dendritic branching. The authors conclude that dendritic trafficking of lysosomes is properly mediated by molecular interaction of TMEM106B and MAP6. This paper is well constructed, and results are finely arranged. In particular, experimental data concerning knockdown studies of TMEM106B, and knockdown and overexpression studies of MAP6 are well demonstrated and highly evaluated. However, the localization of lysosomes in primary neurons evidenced by immunohistochemistry for TMEM106B and GFP-Rab7a is very important in the present study. The following questions should be addressed in this study.
1. Although immunocytochemical localization of TMEM106B and MAP6 was presented in primary neurons, no precise localization of these proteins was described. It is better to explain whether these proteins are localized in axons, although they show somatodendritic localization. 2. Page 5, the first paragraph in the Results section: The presence of cathepsin B is shown as the proform at a molecular mass of 40 kDa and the heavy chain form at a molecular mass of 25 kDa. In HeLa cells, couldn't the single chain form be detected around 29 kDa in the cells even when the proform appeared? Why don't the authors examine this processing, using primary cultures? Moreover, how about HeLa cell size after TMEM106B knockdown? 3. Page 15, lines 3-10: This study do not show any evidence for lysosomes that work as a source of membrane lipids. Therefore, the expression, "Thus, a shift towards retrograde transport of lysosomes likely leads to dendrite withering through loss of lipid membranes in distal dendrites" is too much speculative. 4. Page 15, the second paragraph: The present study did not show the evidence for localization of lysosomes shown by TMEM106B and MAP6 in the axon of primary neurons. In particular, primary neurons at DIV4 are still very immature and different from those at DIV7+5 or 14+5. The data showing that axonal length is 40% more extended in TMEM106B knockdown than in control are not comparable to the data of reduced dendritic arborization in TMEM106B knockdown. It is better to measure the length of axons in TMEM106 knockdown neurons at DIV17+5 when the neurons are thought to be mature in form. Thank you for sending the detailed point-by-point response. I agree with the proposed plan of action and the suggested experiments to further strengthen the link between the trafficking defects and dendritic phenotypes. I would therefore like to invite you to submit a suitably revised manuscript along the lines as indicated in your point-by-point response.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
1st Revision 07 October 2013
General Response to the reviewers
New data added in the revised version of the manuscript:
• Quantitative analysis confirms colocalization of TMEM106B with LAMP1 (late endosomes/lysosomes) but not transferrin receptor TfR (early endosomes/recycling endosomes) and SV2 (synaptic vesicles) (new Figure S2 ) • Quantitative analysis of the longest dendrite confirms that the primary dendrite is elongated upon TMEM106B knockdown (new Figure S4A ) • We show axonal localization of TMEM106B ( Figure S5C ), but we find no effect of TMEM106B knockdown on lysosomal trafficking in axons ( Since the other reviewers raised no major concerns about the data in Hela cells we would prefer to leave the data in the manuscript, but we could delete it if requested by the editor.
The distribution of TMEM106B in neurons and its colocalisation with LAMP1 have already been
reported (J Neurosci. 2012 32(33): 11213-11227) Figure 2 and S2 are very different, raising concerns on the heterogeneity of cells and possibly phenotype.
We followed the reviewer's suggestion and quantitatively analyzed the colocalization of TMEM106B with lysosomes, synaptic vesicles and early endosomes (new Figure S2) . We also confirm that some TMEM106B is present in axon without affecting lysosomal trafficking in this compartment (new Figure S5C -E).
Regarding the difference of Figures 2 and S2: For proper colocalization analysis Figure 2 shows only one focal plane. The neuron in the center of the image is hit in the dendritic plane, while the other two neurons are sectioned at a level focusing the somatic TMEM106B and lysosomes. Figure  S2 show projection image taken at a lower intensity to properly analyze TMEM106B knockdown, which emphasize the dense somatic TMEM106B and lysosomes. We added this important information to the figure legend. Moreover, primary neuron cultures unfortunately show batch to batch variations. We therefore performed all quantification experiments at least three times from different cultures.
3.
A phenotype generated by TMEM106B knockdown is the increase in primary dendrite length (more visible with shRNA 1; Figure 3B) Figure 6 )?
Our additional analysis confirmed the reviewer's impression that the remaining dendrites in TMEM106B knockdown cells are longer (shown in the new Figure S4A ). The main dendrite seems to be particularly resistant to degeneration (e.g. Hoogenraad et al, Nat Neuro 2005).
In dissociated neuron culture, axons are growing rapidly and it becomes very hard to trace single cell axons at later developmental stages (DIV 7+5), precluding the analysis of lysosomal trafficking in axons at this stage. However, at early stages (DIV4), when we observed axonal length phenotype, individual axons can be easily identified. We therefore could analyze lysosomal trafficking in axon only at DIV0+4. This new data ( Figure S5D -E) suggests that TMEM106B affects only dendritic but not axonal trafficking of lysosomes.
Why overexpression of T106B does not cause an increase in distal branching as MAP6 downregulation? This phenotype is also not triggered by nocodazole treatment, demonstrating that these treatments do not completely phenocopy each other.
For the rescue experiments we only examined physiological levels of TMEM106B ( Figure 3C ), TMEM106B overexpression leads to unphysiological aggregates (compare Chen-Plotkin et al, J Neuroscience 2013), which may obstruct the dendrites and prevents a meaningful analysis of TMEM106B overexpression.
The slight differences in dendritic branching upon rescue with MAP6 knockdown and nocodazole treatment are not entirely unexpected. We cannot exclude that the pharmacological treatment with nocodazole or genetically knockdown of MAP6 shows differential effects in addition to changing lysosomal transport and microtubule dynamics. We discuss this in the revised manuscript on page 11. Figure 6 and S5 are rather low for a cytoplasmic dynein based process -only one lysosome seems moving in the kymograph in Figure 5A . The effect of TMEM106B knockdown is noticeable but rather limited.
The speed and the frequency of lysosomal movement in the experimental conditions of

Is this the case in axons as well? Are the effects of TMEM106B knockdown on the dynamics of lysotracker-positive organelles similar?
Lysotracker staining was too dim for live-imaging analysis at the necessary sampling rate. It is not clear whether the lysosomal transport affected by TMEM106B is dynein or kinesin based, because both mechanisms mediate bidirectional transport in dendrites due to the bidirectional arrangement of microtubules. To our knowledge nobody has studied transport of lysosomes in dendrites in detail so far. The reported speed of organelle transport in dendrites varies from ranges from 0.21 µm/s to 1.08 µm/s (e. 
The percentage of moving lysosomes in shMAP6 double knockdown samples seems much higher than shCtrl (Figure 7A, B), yet the relative vesicle number of moving organelles is very similar in the quantification in panel 7C. Are these kymographs representative? The results shown in this figure do not support the link between the altered dendritic transport of lysosomes and dendritic branching and the phenotypes shown in Figures 5 and 6.
Dissociated neuron cultures are as primary cultures prone to batch to batch variation. All figures showing quantitative analysis of trafficking are the result from at least 3 independent experiments (each at least 8 neurons). Each experiment by itself shows similar effects with statistically significant differences. The bar graphs show the mean and standard error of the independent experiments. In all kymograms the majority of lysosomes remain stationary during the 5 minute observation, but the mobile lysosomes may dominate the image visually. The depicted kymograms are representative for the mean +/-standard error.
The first version of our manuscript already showed evidence for a link of dendritic trafficking of lysosomes and dendritic branching. MAP6 overexpression and TMEM106B knockdown both affect trafficking of lysosomes and dendritic branching in the same direction, which is consistent with a causal link (Figures 5, 6 and 7) . Moreover, inhibiting lysosomal biogenesis with dominant negative Rab7 impairs dendritic branching ( Figure S4B /C).
For the revised version of the manuscript we used dominant negative Rab interacting lysosomal protein (dnRILP) to manipulate lysosomal trafficking independent of TMEM106B/MAP6 and analyzed the effects on dendritic branching (new Figure 8) . In contrast to TMEM106B knockdown, dnRILP enhances anterograde trafficking of lysosomes in dendrites and promotes dendritic branching. Importantly, expression of dnRILP in TMEM106B knockdown neurons restores the balance of anterograde and retrograde lysosomal transport and also remedies the dendrite loss.
One of the predictions of the model shown in Figure 8 is that the modulation of lysosome transport by TMEM106B and MAP6 should be different in proximal and distal dendrites. Is this the case?
We did not claim in our model in Figure 9 any difference between trafficking in distal and proximal dendrites in TMEM106B knockdown neurons. MAP6 knockdown by itself seems to preferentially enhance branching of distal dendrites, although the tendency was less pronounced in our new experiments, indicating that batch to batch variations may play a role (compare Figures 5D and the new Figure S7B ). However, MAP6 knockdown also rescues the proximal dendrite loss in TMEM106B knockdown cells ( Figure 5D ). The increase in distal branching in MAP6 knockdown cells may be due to other mechanisms independent of TMEM106B and lysosomes, because manipulating lysosomal trafficking by dnRILP affects both distal and proximal branching equally (new Figure 8C/D) . We discuss this in the main text of the revised manuscript (page 11).
Page 3-4. The relationship of the different TMEM106B variants with human neurodegeneration is not very clearly explained. The wording should be simplified and made more precise in places (e.g. transmembrane domain in type 2 orientation).
We apologize for any misunderstanding. We now highlight the genetic data on TMEM106B variants and we have tried to simplify the introduction were possible.
Referee #2
In It is true that rescue experiments are an excellent way to validate an RNAi-based phenotypes. The initial manuscript already contained such rescue experiments for TMEM106B knockdown in Figure  3D to confirm specificity of the branching defect. We took great efforts to achieve the results using lentiviral expression, because simple plasmid based overexpression of TMEM106B leads to aggregate formation (Chen-Plotkin et al, J Neuroscience 2013).
We now added rescue experiments for the effect of TMEM106B on dendritic transport of lysosomes (new Figure S7C/D) . We could also rescue the enhanced distal branching in MAP6 knockdown neurons by overexpressing human MAP6 (new Figure S7A /B).
2. Fig 2a. The significance and specificity of the TMEM106B/Lamp1 colocalization should be statistically tested using an appropriate negative control. Does MAP6 also colocalize to lysosomes?
We quantifiy the colocalization of TMEM106B and LAMP1 using SV2 (synaptic vesicles) and transferrin receptor TfR (early endosomes) as negative controls (new Figure S2) .
The interaction of TMEM106B and MAP6 has been established through mass spectrometry, coimmunoprecipitation (in rat brain and transfected cells) and subcellular fractionation (Figure 4 and S6). In fixed co-stainings the colocalization of MAP6 and TMEM106B is moderate (new Figure  S6B) , which is not surprising as MAP6 is very abundant in dendrites and the interaction is presumably transient ( Figure S6B ). However, live imaging of MAP6-GFP and LAMP1-RFP in neurons shows that overexpressed MAP6-GFP travels with a fraction of moving LAMP1-GFP labeled lysosomes (new Figure S9 ) similarly to our model ( Figure 9B ).
Figure Long-term dual-color time lapse study of dendritic arborization and lysosomal trafficking should better explain the functional relationship between these two phenotypes.
The high sampling rate (1 Hz) required to analyze lysosome trafficking precludes prolonged imaging due to bleaching and phototoxicity. To corroborate the function relationship of lysosomal transport and dendritic branching, we manipulated lysosomal trafficking independent of MAP6/TMEM106B using dominant negative Rab interacting lysosomal protein (dnRILP) and analyzed the effects on dendritic branching (new Figure 8) . In contrast to TMEM106B knockdown, dnRILP enhances anterograde trafficking of lysosomes in dendrites and promotes dendritic branching. Importantly, expression of dnRILP in TMEM106B knockdown neurons restores the balance of anterograde and retrograde lysosomal transport and also remedies the dendrite loss.
Figure Please also show the colocalization of MAP6 and TMEM106B to the lysosomes by fluorescently-tagged construct transfection.
Unfortunately, GFP-tagged TMEM106B forms large cellular aggregates and thus cannot be used for such experiments. Co-expression of MAP6-GFP and Lamp1-RFP shows joint trafficking of both proteins on lysosomes (new Figure S9B) .
Y2H results should be precisely included to show what domains of these molecules are responsible for the interaction.
Coimmunoprecipiation with different splice variants and truncated forms of MAP6 together with the cytoplasmatic N-terminus of TMEM106B confirms the interaction of both proteins. We were able to map the interaction to the cytoplasmic N-terminus of TMEM106B (amino acids 1-93) and the Cterminus of MAP6 (amino acids 615-952)
Figures 5 and 6. Please add knockdown-rescue studies.
See explanation in point 1 and the new Figure S7 .
Referee #3
The We now show that TMEM106B is indeed also present in axons (new Figure S5A ) although knockdown does only affect axonal length ( Figure S5B /C), but not lysosomal transport in this compartment (new Figure S5D/ Figure 1 shows expression of the immature and mature Cathepsin B exactly at the expected molecular weight. The Cathepsin B antibody does not work in rat neurons and cultured neurons show only low levels of mature Cathepsin D, which do not change upon TMEM106B knockdown.
In an independent study in mouse brain we noticed that significant Cathepsin maturation starts only at the age of 3 months, indicating that embryonic cultures are not an appropriate system to study Cathepsin function.
Our data indicates that TMEM106B knockdown does not affect size in Hela cells 3 days after transfection. This is now mentioned on page 5. We confirmed colocalization of TMEM106B in axonal lysosomes (new Figure S5A ). We agree that there are differences in development between neurons in culture at DIV4 compared to DIV 17+5. We have chosen these different developmental stages to address specifically axonal or dendritic development. Early stages (DIV4) are suitable for axonal analysis because single axons can be identified, but at this developmental stage dendrites are very short and rarely branched. Later developmental stages are have fully developed and branched dendrites, but unfortunately due to rapid axonal growth the tortuous full length axons from a single cell cannot be traced, which precluding axon analysis in cultured neurons at this age.
Acceptance letter 27 October 2013
Thank you for submitting your revised manuscript to the EMBO Journal. Your manuscript has now been re-reviewed by referees # 1 and 2 and as you can see below they both appreciate the revisions carried. I am therefore very pleased to accept the paper for publication here.
Also, we now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figure? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The PDF files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this just contact me.
Thank you for contributing to the EMBO Journal!
REFEREE REPORTS
Referee #1
The authors made a significant effort in revising this manuscript and adding data requested by the three reviewers. The new results are of the highest quality and in general, they significantly contribute to the overall conclusions of this work. Although few areas of the manuscript remain unconvincing (e.g. providing a causal link the phenotype observed and the model proposed -see answer to point 6), the amended manuscript is improved and will significantly contribute to the field.
Referee #2
In this revision the authors have considerably improved the manuscript along with the previous reviewers' suggestions and now the data became much firmer. This reviewer will recommend its publication in the present form.
